ArticleCureus2025
Trends in Mortality From Malignant Neoplasms of the Liver and Intrahepatic Bile Ducts in the United States: A Retrospective Analysis From 1999 to 2020.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Trends and disparities in intrahepatic cholangiocarcinoma mortality in the United States, 1999-2024: a CDC WONDER analysis.Frontiers in oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPrimary malignant liver tumors constitute a significant global health challenge. We conducted an analysis of mortality trends across all forms of primary liver cancers, including hepatocellular carcinoma (HCC), cholangiocarcinoma, and other less prevalent types, to enhance our understanding of the overall burden these cancers impose on the US population.
methodThe Centers for Disease Control and Prevention Wide-Ranging Online Data for Epidemiologic Research (CDC WONDER) database was analyzed, and the International Classification of Diseases, 10th Revision (ICD-10), codes were utilized to identify deaths from primary malignant neoplasms of the liver from 1999 to 2020 in patients aged 25 or older. The age-adjusted mortality rates (AAMR/100,000) for the population were extracted, and trends were analyzed for age, gender, race, and year. Result: There were a total of 445,389 deaths from primary liver cancer from 1999 to 2020. AAMR increased from 6.95 in 1999 to 10.12 in 2020. Gender analysis showed that both sexes have shown a gradual increase in AAMR over the course of years. The mean AAMR for males was 13.09 per 100,000 population (range: 12.31-13.87; SD: 1.75), which was more than twice the rate observed in females (mean: 5.45; range: 5.16-5.74; SD: 0.66). Race analysis showed that Asian or Pacific Islanders are the only race that has shown an overall decreasing trend in mortality from liver cancer, with AAMR decreasing from 15.68 in 1999 to 12.15 in 2020. Despite the decreasing trend, Asian or Pacific Islanders still have the highest mean AAMR (mean: 14.83; range: 14.21-15.46; SD: 1.41), followed by Hispanics (13.15), Black or African Americans (11.52), American Indians or Alaskan Natives (10.51), and finally Whites (8.32). Discussion: An important aspect of understanding the disparities in mortality from primary liver cancer will be to see these disparities in the context of HCC, which accounts for 85% of primary liver malignancies. The decreasing mortality trend from primary liver cancer observed in Asians is consistent with a decreasing trend in mortality from HCC due to a decreasing incidence of hepatitis B virus (HBV). The increased mortality from primary liver cancer among males noted throughout the study period can be attributed to higher incidences of HBV and hepatitis C virus (HCV) infections, as well as greater alcohol consumption, all of which contribute to the development of HCC. Additionally, there is evidence to support that estrogens play a protective role, limiting liver inflammation and fibrogenesis and counteracting the development of HCC in females.
conclusionWith an increasing mortality trend from primary malignant neoplasms of the liver, further research is needed to mitigate the risk factors and advance the treatment modalities for liver cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.